Department of Internal Medicine (Imaging Science Center), School of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil.
Ultrasound Med Biol. 2012 Oct;38(10):1689-94. doi: 10.1016/j.ultrasmedbio.2012.06.006. Epub 2012 Aug 21.
The aim of this study was to evaluate the prognostic implications of the sonographic appearance of prostate cancers. All patients with biopsy-proven prostate cancer between January 2003 and July 2004 (and at least 5 years of follow-up) were selected retrospectively. After exclusions, 101 patients constituted our study population and were divided into isoechoic (or nonvisible) and hypoechoic (or visible) lesion. The clinical outcomes of these two groups were compared. The outcomes for the two groups were significantly different (p < 0.01). For nonvisible lesions, 37 of the 41 patients (90.2%) had no disease relapse and 2 (4.9%) had biochemical failure. For the visible lesions, 37 of the 60 (61.6%) patients were free of recurrence, 7 (11.7%) had systemic metastases and 10 (16.7%) died of complications related to prostate cancer. Our data show that patients with nonvisible prostate cancer had significantly better outcomes than patients with visible lesions during a five-year period of evaluation.
本研究旨在评估前列腺癌超声表现的预后意义。回顾性选取 2003 年 1 月至 2004 年 7 月间(并至少随访 5 年)经活检证实为前列腺癌的所有患者。排除后,共有 101 例患者入组,并分为等回声(或不可见)和低回声(或可见)病变组。比较两组的临床结局。两组的结果有显著差异(p<0.01)。在不可见病变组中,41 例患者中有 37 例(90.2%)无疾病复发,2 例(4.9%)发生生化失败。在可见病变组中,60 例患者中有 37 例(61.6%)无复发,7 例(11.7%)发生全身转移,10 例(16.7%)死于与前列腺癌相关的并发症。我们的数据表明,在五年的评估期内,不可见前列腺癌患者的预后明显优于可见病变患者。